Considering the importance of the protective function and prognostic role of CD169+ Mφ in both HCC and GC, it may be worth investigating whether the selective overexpression of CD169 might represent a novel therapeutic approach to reprogram the anti-tumor activities of Mφ. Here, SIGLEC1 is linked to neoplasm.